Stockreport

NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heter...

NewAmsterdam Pharma Company N.V. - Ordinary Shares  (NAMS) 
PDF -- 21% observed reduction in major adverse cardiovascular events favoring obicetrapib at one year – Observed to be well-tolerated with safety results comparable to pl [Read more]